


# How specific and sensitive is your PSA test?

## PSA circulates in different forms in the blood.

- You probably know that Complexed PSA (cPSA) has been shown to increase in patients with prostate cancer.<sup>1</sup>
- But did you know that Siemens Healthcare Diagnostics method accurately measures cPSA?<sup>2</sup>

That means you have a test that delivers specificity and reliability where you need it. A test you can count on.



Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care.

ADVIA Centaur and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

### Global Division

Siemens Healthcare Diagnostics Inc.  
1717 Deerfield Road  
Deerfield, IL 60015-0778  
USA  
[www.siemens.com/diagnostics](http://www.siemens.com/diagnostics)

### Siemens Global Headquarters

Siemens AG  
Wittelsbacherplatz 2  
80333 Muenchen  
Germany

### Global Siemens Healthcare Headquarters

Siemens AG  
Healthcare Sector  
Henkestrasse 127  
91052 Erlangen  
Germany  
Telephone: +49 9131 84 - 0  
[www.siemens.com/healthcare](http://www.siemens.com/healthcare)

[www.siemens.com/diagnostics](http://www.siemens.com/diagnostics)

Order No. A91DX-0331091-C2-4A00 | Printed in USA | © 2008 Siemens Healthcare Diagnostics Inc.



## When Testing for Prostate Cancer, Just How Specific and Sensitive is Your PSA Test?

**Specificity. Reliability. Sensitivity.**

Answers for life.



**SIEMENS**

# Here's how:

## Improving specificity.

- cPSA has been shown to be 10-22% more specific than a commercially available tPSA.<sup>3,4</sup>
- Now you can use cPSA instead of PSA as an aid in the detection of prostate cancer in conjunction with DRE.


cPSA included in the NCCN guidelines.



## Siemens Healthcare Diagnostics cPSA: Specificity where you need it.

- Studies have shown that almost 30% of prostate cancers are detected in the low PSA range of 2-6 ng/mL.<sup>5</sup>


It's important that your test delivers the results you need.



## Siemens cPSA is more reliable and stable.

- Results of cPSA testing have been shown to stay constant over time.<sup>2,6</sup>

That's important since Free PSA can decrease by an average of 9% after 24 hours, even under normal sample handling conditions.<sup>7</sup>



## The right test, the right time. Siemens cPSA.

- Specificity without compromising sensitivity makes it the right test for first line detection.
- Specificity where you need it.
- Increased stability and reliability for greater confidence in your results.
- Clear and consistent results so you can trust it as your first line prostate cancer detection test.

Probability of Positive Biopsy Result (DRE Not Suspicious for Cancer)<sup>8</sup>

cPSA (ng/mL)	N	N Cancers	Risk (%)	95% Confidence Interval	
<3.6	138	33	23.9	16.8	31.0
3.6 to 5.0	93	40	43.0	32.9	53.0
>5.0	131	66	50.4	41.6	58.9

Probability of positive biopsy results for DRE alone negative is 38.4% (139/362; 95%CI 33.4% - 43.6%).

Probability of Positive Biopsy Result (DRE Suspicious for Cancer)<sup>8</sup>

cPSA (ng/mL)	N	N Cancers	Risk (%)	95% Confidence Interval	
<3.6	63	34	54.0	41.7	66.3
3.6 to 5.0	37	23	62.2	46.5	77.8
>5.0	52	39	75.0	63.2	86.7

Probability of positive biopsy results for DRE alone positive is 63.2% (96/152; 95%CI 55.0% - 70.8%).

## References:

- Stenman, et al. *Cancer Research*; 51:222-226, 1991.
- Allard, et al. *International J of Biological Markers*; 14, No. 2: 73-83, 1999.
- Brawer, et al. 4-10 ng/mL (n=439) *J of Urol*; 163: 1476-1480, May 2000.
- Okegawa, et al. 2.5-4.0 ng/mL (n=515) *J of Urol*; 165(6): 1930-1936, 2000.
- Partin, et al. Final Results of a Multicenter Prospective Evaluation of Complexed PSA for Early Detection of Prostate Cancer. *J of Urol*; 167(4): 207, Abstract 834, 2002.
- Okihara, et al. 2.5-4.0 ng/mL (n=151) *J of Urol*; 165(6): 1930-1936, 2001.
- Jung, et al. Stability of PSA forms in Serum at 40C (n=15) *Clin Chem Lab Med* 2000; 38(12): 1271-1275.
- Siemens Healthcare Diagnostics Centaur® cPSA Package Insert.

For detailed information on this test, including limitations or interferences that may affect the interpretation of test results contact your clinical laboratory.

For more information regarding the NCCN (National Comprehensive Cancer Network) Guidelines, please visit [http://www.nccn.org/physician\\_gls/f\\_guidelines.html](http://www.nccn.org/physician_gls/f_guidelines.html)